Elevating theranostics: The emergence and promise of radiopharmaceutical cell‐targeting heterodimers in human cancers
Open Access
- 6 April 2024
- journal article
- review article
- Published by Wiley in iRADIOLOGY
- Vol. 2 (2) , 128-155
Abstract
Optimal therapeutic and diagnostic efficacy is essential for healthcare's global mission of advancing oncologic drug development. Accurate diagnosis and detection are crucial prerequisites for effective risk stratification and personalized patient care in clinical oncology. A paradigm shift is emerging with the promise of multi‐receptor‐targeting compounds. While existing detection and staging methods have demonstrated some success, the traditional approach of monotherapy is being reevaluated to enhance therapeutic effectiveness. Heterodimeric site‐specific agents are a versatile solution by targeting two distinct biomarkers with a single theranostic agent. This review describes the innovation of dual‐targeting compounds, examining their design strategies, therapeutic implications, and the promising path they present for addressing complex diseases.Keywords
Funding Information
- Foundation for the National Institutes of Health (R01CA269221, R01CA225837)
This publication has 128 references indexed in Scilit:
- Preparation and preclinical evaluation of 68Ga-iPSMA-BN as a potential heterodimeric radiotracer for PET-imaging of prostate cancerJournal of Radioanalytical and Nuclear Chemistry, 2018
- Preclinical evaluation of a bispecific low‐molecular heterodimer targeting both PSMA and GRPR for improved PET imaging and therapy of prostate cancerThe Prostate, 2014
- Peptides for Nuclear Medicine Therapy: Chemical Properties and Production2013
- Radiolabeled Heterobivalent Peptidic Ligands: an Approach with High Future Potential for in vivo Imaging and Therapy of Malignant DiseasesChemMedChem, 2013
- Substitution of Gly with Ala enhanced the melanoma uptake of technetium-99m-labeled Arg-Ala-Asp-conjugated alpha-melanocyte stimulating hormone peptideBioorganic & Medicinal Chemistry Letters, 2012
- Profiling gastrin‐releasing peptide receptor in prostate tissues: Clinical implications and molecular correlatesThe Prostate, 2011
- Replacement of the Lys linker with an Arg linker resulting in improved melanoma uptake and reduced renal uptake of Tc-99m-labeled Arg-Gly-Asp-conjugated alpha-melanocyte stimulating hormone hybrid peptideBioorganic & Medicinal Chemistry, 2010
- A low molecular weight PSMA-based fluorescent imaging agent for cancerBiochemical and Biophysical Research Communications, 2009
- Design, Synthesis, and Biological Evaluation of Somatostatin-Based RadiopeptidesChemistry & Biology, 2006
- Immunoscintigraphy of prostatic cancer: Preliminary results with 111in‐labeled monoclonal antibody 7E11‐C5.3 (CYT‐356)The Prostate, 1991